Abstract
5-fluorouracil (5-FU) is widely used in the treatment of cancer. Over the past 20 years, increased understanding of the mechanism of action of 5-FU has led to the development of strategies that increase its anticancer activity. Despite these advances, drug resistance remains a significant limitation to the clinical use of 5-FU. Emerging technologies, such as DNA microarray profiling, have the potential to identify novel genes that are involved in mediating resistance to 5-FU. Such target genes might prove to be therapeutically valuable as new targets for chemotherapy, or as predictive biomarkers of response to 5-FU-based chemotherapy.
Original language | English |
---|---|
Pages (from-to) | 330-338 |
Number of pages | 9 |
Journal | Nature Reviews. Cancer |
Volume | 3 |
DOIs | |
Publication status | Published - May 2003 |
Keywords
- Animals
- Antimetabolites, Antineoplastic
- Biological Markers
- Dihydrouracil Dehydrogenase (NADP)
- Fluorouracil
- Humans
- Interferons
- Microsatellite Repeats
- Oligonucleotide Array Sequence Analysis
- Oxidoreductases
- RNA
- Thymidine Phosphorylase
- Thymidylate Synthase
- Tumor Suppressor Protein p53
ASJC Scopus subject areas
- Cancer Research